BioSpace News Archive

Anthony P. Castore, CEO of Ziering Medical, the leader in hair restoration in the United States , has been appointed to the Aesthetic Industry Association [AIA] advisory board. Mr. Castore is a seasoned business expert with a solid reputation for implementing programs, protocols, business development strategies and efficien

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration announced today that enrollment in the 700-patient, phase 3 clinical trial for dry eye syndrome (ARISE-3) is expected to be completed in November, 2020, and that th

Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in sickle cell disease treatment, announced today that it has sold all remaining common shares of South Korea -based Telcon RF Pharmaceutical Inc. (KOSDAQ: 200230) in accordance with the Telcon agreement reported by Emmaus in its Current Report on Form 8-K fi

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced a partnership with The Foundry – a medical device company incubator – dating back to mid-2017 to invest in and create a company with the goal of developing an innovat

WAKIX is the first and only non-scheduled treatment approved for excessive daytime sleepiness or cataplexy in adult patients with narcolepsy

NuVera Medical, Inc., a portfolio company of Shifamed LLC focused on enabling a new era in transcatheter cardiac interventions through the advancement of current 4D ICE imaging, today presented positive r

Funds Will Support Further Development of Interventional Technologies for Navigation and Treatment of Diseases Across the Lung

PierianDx, the leading clinical genomics informatics company, and Pillar Biosciences, a leading next-generation sequencing clinical oncology company, today announced a partnership that enables Pillar Biosciences to sell directly the PierianDx cli

Large Study Demonstrates Exceptional Safety and High Procedural Success With Cardiovascular Systems’ Diamondback 360 ® Coronary Orbital Atherectomy System (OAS) ST. PAUL, Minn.--( BUSINESS WIRE )-- Cardiovascular Systems, Inc. (CSI ® ) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that results from a large retrosp

Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, and U-Diagnostics B.V., a Dutch medical laboratory, specialized in analysis in the field of clinical chemistry and hematology, medical microbiology, medical immunology